Transdermal Diagnostics is developing breakthrough needle-free wearables to transform chronic disease management starting with diabetes. Our patented extraction principle eliminates pain, reduces costs and environmental impact, driving equitable health monitoring. ProblemDiabetes affects 589 million people globally, with 50% undiagnosed and 541 million in pre-diabetic stages. Current Continuous Glucose Monitoring (CGM) solutions require painful needle penetration or surgical implants, causing poor adherence and suboptimal disease management. The high cost and increased medical waste make available CGMs inaccessible in resource-limited settings, widening health disparities and raising environmental concerns. The result: escalating health risks, continued patient suffering, strained healthcare systems, unsustainable clinical practices, and over $1 trillion in global diabetes-related spending in 2024. Solution Transdermal Diagnostics is developing the world's first 100% needle-free, pain-free, affordable, and wearable Continuous Glucose Monitor. We use patented, validated extraction technology and optimised sensor arrays to eliminate invasive calibration requirements. Our high-speed printing processes and reusable design lower manufacturing costs and cut waste by 88%, reducing environmental impact. By removing primary barriers of pain, discomfort and cost, our solution dramatically improves patient compliance, driving better health outcomes while reducing the healthcare, economic and environmental burdens of diabetes care.MarketOur innovation targets 1.1 billion people across Type 1, Type 2 and pre-diabetic populations, with an estimated serviceable market exceeding £1.4B.ContactTransdermal Diagnostics LinkedInTransdermal Diagnostics Website This article was published on 2025-09-17
